STA-1
Phase 2Small molecule
STA-1 is one of 13 small molecule programs targeting Vascular Dementia. It is currently in Phase 2.
1
Indications
2
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Vascular Dementia
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Lexapro
AbbVieApproved
Aricept
EisaiApproved
Cialis
Eli LillyApproved
Pletal
OtsukaApproved
Exelon
NovartisPhase 3
Cerebrolysin
EEver Neuro Pharma GmbH
Approved
Reminyl
WWim Janssens
Phase 3
Donepezil Hydrochloride
EisaiPhase 3
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for STA-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSinphar Pharmaceutical Co., Ltd